Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including NEWTON, Mass., Dec. 2, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 4,800 restricted stock units (RSUs) to two newly-hired employees. These RSU awards were granted as of November 30, 2024 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
馬薩諸塞州牛頓，2024年12月2日 /PRNewswire/ -- karyopharm therapeutics公司（納斯達克：KPTI），一家領先創新癌症療法的商業階段藥品公司，今天宣佈公司向兩名新聘員工授予總計4,800個限制性股票單位（RSUs）。這些RSU獎勵於2024年11月30日（「授予日期」）根據公司2022年誘導股票激勵計劃（已修訂）授予，作爲根據納斯達克上市規則5635(c)(4)與karyopharm就業的新員工進入僱傭關係的重要誘因。
Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of each RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates. In addition, each RSU award will be immediately exercisable in full if, on or prior to the first anniversary of the consummation of a "change in control event," the employee's employment is terminated for "good reason" by the employee or terminated without "cause" by Karyopharm (as such terms are defined in the applicable RSU agreement).
每個RSU獎勵將在三年內分期歸屬，其中每個RSU獎勵股份的33 1/3％將在授予日之後的三個連續週年紀念日上獲得。每個RSU獎勵的歸屬取決於員工在適用歸屬日期之前作爲Karyopharm的僱員或其他服務提供商的繼續服務。此外，如果在「控制權變更事件」完成的第一週年紀念日之前，員工因「良好的理由」被員工解僱或被Karyopharm無「原因」解僱，則每個RSU獎勵將立即完全行權（如適用的RSU協議中所定義）。
About Karyopharm Therapeutics
關於Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit , and follow us on LinkedIn and on X at @Karyopharm.
Karyopharm Therapeutics公司（納斯達克：KPTI）是一家商業階段的藥品公司，致力於開創新型癌症療法，其動力來自對癌症患者非凡的力量和勇氣的信仰。自成立以來，Karyopharm一直是口服化合物領域的行業領導者，涉及核蛋白輸出失調，這是癌症發生的基本機制。Karyopharm的首個口服輸出蛋白1（XPO1）抑制劑和首創藥物XPOVIO（西立諾司）在美國獲批，由公司在三個腫瘤治療適應症中銷售。它還在越來越多的非美國領土和國家，包括歐洲、英國（作爲NEXPOVIO）和中國，獲得了各種適應症的監管批准。Karyopharm專注於多種高度不滿足需求的癌症適應症，包括多發性骨髓瘤、子宮內膜癌、骨髓纖維化和瀰漫大B細胞淋巴瘤（DLBCL）。有關我們的人員、科學和管線的更多信息，請訪問 ，並在領英和X上關注我們@Karyopharm。
XPOVIO and NEXPOVIO are registered trademarks of Karyopharm Therapeutics Inc.
XPOVIO和NEXPOVIO是Karyopharm Therapeutics Inc.的註冊商標。
SOURCE Karyopharm Therapeutics Inc.
SOURCE Karyopharm Therapeutics Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎？
譯文內容由第三人軟體翻譯。
